Diagnostic services provider Metropolis Healthcare Ltd on Tuesday (November 3) reported a 43.2% year-on-year (YoY) increase in net profit to ₹75.3 crore for the second quarter, compared with ₹52.6 crore in the corresponding quarter last year. Revenue rose 15.8% YoY to ₹496.8 crore from ₹429.1 crore.
Earnings before interest, tax, depreciation and amortisation (EBITDA) increased 24.1% to ₹134 crore from ₹108 crore. EBITDA margin expanded to 27% from 25% in the year-ago quarter, an improvement of 200 basis points.
Patient volume increased 10% YoY to 4.1 million, while test volume rose 11% to 8.7 million during the quarter.
B2C, B2B and specialty revenue
Business-to-consumer (B2C) revenue grew 17% YoY to ₹289 crore, driven by lifecycle-led customer engagement, targeted micro-marketing initiatives and brand recall. Business-to-business (B2B) revenue increased 15% to ₹208 crore, supported by the addition of new clients and higher uptake of specialised tests among existing clients.
ALSO READ | Metropolis Health shares extend gains on positive management commentary; Analyst sees nearly 14% upside
TruHealth revenue rose 20% YoY to ₹86 crore, driven by premiumisation and more customers opting for preventive care. Specialty revenue also increased 20% to ₹198 crore, led by advanced genomic testing and accelerated growth in cancer testing.
Revenue per patient (RPP) increased 6% YoY to ₹1,221 despite the absence of any price increase benefit. Revenue per test (RPT) improved 5% to ₹572, supported by a richer test mix and improved realisations.
Tier III cities remained the fastest-growing markets, with revenue increasing around 20% YoY. Metropolis now reaches around 750 towns through 5,119 service points.
Dividend declared
The company’s board declared an interim dividend of ₹1 per equity share of face value ₹2 each for FY27. November 9, 2026, has been fixed as the record date to determine shareholders eligible for the interim dividend. The dividend will be paid within 30 days of its declaration.
ALSO READ | Metropolis Healthcare aims to raise specialty revenue share to 45%
Ameera Shah, Promoter and Executive Chairperson, Metropolis Healthcare Ltd, said, “We are pleased with our H1FY27 performance, with revenue up 16% and no price increase, reflecting the trust of patients and clinicians.
As diagnostics becomes central to preventive and precision healthcare, we are building Metropolis into a stronger, differentiated and future-ready platform. We will deepen our science and genomics expertise, use technology to transform the patient experience, and pursue strategic acquisitions that sharpen our competitive edge.
From a 1,000-gene oncology panel to a blood-based Alzheimer’s test, our newest offerings bring earlier answers to complex clinical questions. Under Metropolis 3.0, our priority is not simply to expand our footprint, but to create the capabilities that will define the next phase of Indian diagnostics.”
ALSO READ | Metropolis Healthcare Q1 profit rises 26% as TruHealth, Tier III markets gain momentum
Surendran Chemmenkotil, Managing Director, Metropolis Healthcare Ltd, said, “Q2FY27 was a strong quarter, with EBITDA up 24% and margin expanding 180 basis points to 27.2%, reflecting steadily improving operating performance.
PAT was up 43%, supported by gains across B2C, B2B, TruHealth and Specialty, higher test volumes and a wider network. For the rest of the year, we will extend our presence in Tier II and III towns, where demand is rising fastest, scale our wellness and specialty portfolio, and broaden engagement with doctors and hospitals. Disciplined execution and greater productivity will remain central to sustaining this growth.”
Shares of Metropolis Healthcare Ltd ended at ₹571.20, up by ₹11.10, or 1.98%, on the BSE.